NovaMedica’s goal is not only to become a market leader in its key therapeutic areas but mostly to provide patients and doctors with the access to the most advanced and effective products and technologies. Our portfolio includes pharmaceutical and other medical products, diagnostic equipment, medical devices and technologies designed to provide a comprehensive solution for the whole range of interrelated problems and to bring a real value to the Russian patients.
Key development areas of NovaMedica’s product portfolio are:
NovaMedica will produce migraine drug Relonova in Moscow
23 March 2023
A resource for anti-tumor drugs testing has been launched in Russia
23 March 2023
Building a Community of Trust in Epilepsy & Rare Syndromes
23 March 2023
22 March 2023